The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
86 | 94 | 84 | 65 |
|
Growth
|
30 | 22 | 11 | 57 |
|
Safety
|
65 | 95 | 90 | 82 |
|
Sentiment
|
63 | 6 | 32 | 31 |
|
360° View
|
71 | 61 | 55 | 75 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Analyst Opinions
|
3 | 1 | 5 | 41 |
|
Opinions Change
|
72 | 35 | 50 | 40 |
|
Pro Holdings
|
n/a | 10 | 70 | 82 |
|
Market Pulse
|
64 | 46 | 44 | 12 |
|
Sentiment
|
63 | 6 | 32 | 31 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
86 | 94 | 84 | 65 |
|
Growth
|
30 | 22 | 11 | 57 |
|
|
65 | 95 | 90 | 82 |
|
Combined
|
72 | 89 | 75 | 82 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Price vs. Sales (P/S)
|
80 | 88 | 100 | 89 |
|
Price vs. Earnings (P/E)
|
52 | 69 | 41 | 39 |
|
Price vs. Book (P/B)
|
72 | 88 | 62 | 61 |
|
Dividend Yield
|
91 | 91 | 89 | 77 |
|
Value
|
86 | 94 | 84 | 65 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Revenue Growth
|
6 | 41 | 10 | 76 |
|
Profit Growth
|
78 | 4 | 54 | 52 |
|
Capital Growth
|
17 | 79 | 32 | 17 |
|
Stock Returns
|
66 | 8 | 19 | 55 |
|
Growth
|
30 | 22 | 11 | 57 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Leverage
|
53 | 83 | 85 | 80 |
|
Refinancing
|
58 | 73 | 51 | 39 |
|
Liquidity
|
70 | 97 | 98 | 96 |
|
|
65 | 95 | 90 | 82 |
Discover high‑ranked alternatives to Ono Pharmaceutical and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.
30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.